Clinical, neuroimaging, and molecular spectrum of TECPR2-associated hereditary sensory and autonomic neuropathy with intellectual disability.
Sonja NeuserBarbara BrechmannGali HeimerInes BrösseSusanna SchubertLauren O'GradyMichael ZechSiddharth SrivastavaDavid A SweetserYasemin DincerVolker MallJuliane WinkelmannChristian BehrendsBasil T DarrasRobert J GrahamParul JayakarBarry ByrneBat El Bar-AlumaYael HabermanAmir SzeinbergHesham M AldhalaanMais HashemAmal Al TenaijiOmar IsmaylAsma E Al NuaimiKarima MaherShahnaz IbrahimFatima KhanHenry HouldenVijayalakshmi S RamakumaranAlistair T PagnamentaJennifer E PoseyJames R. LupskiWen-Hann TanGehad ElGhazaliIsabella HermanTatiana MuñozGabriela M RepettoAngelika SeitzMandy KrumbiegelMaria Cecilia PoliUsha KiniStephanie EfthymiouJens MeilerReza MaroofianFowzan Sami AlkurayaRami Abou JamraBernt PoppBruria Ben-ZeevDarius Ebrahimi-FakhariPublished in: Human mutation (2021)
Bi-allelic TECPR2 variants have been associated with a complex syndrome with features of both a neurodevelopmental and neurodegenerative disorder. Here, we provide a comprehensive clinical description and variant interpretation framework for this genetic locus. Through international collaboration, we identified 17 individuals from 15 families with bi-allelic TECPR2-variants. We systemically reviewed clinical and molecular data from this cohort and 11 cases previously reported. Phenotypes were standardized using Human Phenotype Ontology terms. A cross-sectional analysis revealed global developmental delay/intellectual disability, muscular hypotonia, ataxia, hyporeflexia, respiratory infections, and central/nocturnal hypopnea as core manifestations. A review of brain magnetic resonance imaging scans demonstrated a thin corpus callosum in 52%. We evaluated 17 distinct variants. Missense variants in TECPR2 are predominantly located in the N- and C-terminal regions containing β-propeller repeats. Despite constituting nearly half of disease-associated TECPR2 variants, classifying missense variants as (likely) pathogenic according to ACMG criteria remains challenging. We estimate a pathogenic variant carrier frequency of 1/1221 in the general and 1/155 in the Jewish Ashkenazi populations. Based on clinical, neuroimaging, and genetic data, we provide recommendations for variant reporting, clinical assessment, and surveillance/treatment of individuals with TECPR2-associated disorder. This sets the stage for future prospective natural history studies.
Keyphrases
- intellectual disability
- copy number
- magnetic resonance imaging
- autism spectrum disorder
- computed tomography
- obstructive sleep apnea
- multiple sclerosis
- public health
- electronic health record
- emergency department
- endothelial cells
- blood pressure
- single cell
- depressive symptoms
- early onset
- machine learning
- single molecule
- subarachnoid hemorrhage
- brain injury
- blood brain barrier
- african american
- functional connectivity
- diffusion weighted imaging